Tiryaki 2015.

Methods	Study design: placebo controlled, parallel RCT Duration of study: not reported Duration of follow‐up: 24 weeks
Participants	Country: Turkey Setting: single centre Inclusion criteria: kidney transplant recipients with chronic allograft nephropathy, hypertension and albuminuria, treated with RAS inhibition Number: treatment group (24); control group (24) Mean age ± SD (years): treatment group (54 ± 14); control group (52 ± 13) Sex (M/F): treatment group (12/12); control group (11/13) Exclusion criteria: not reported
Interventions	Treatment group Calcitriol: 0.25 µg/d Control group Placebo Co‐interventions Not reported
Outcomes	Urine ACR Urinary angiotensinogen‐to‐creatinine
Notes	Abstract‐only publication. Full‐text publication not identified Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Adverse events not systematically captured
Other bias	Unclear risk	Insufficient information to permit judgement